| scholarly article | Q13442814 |
| P2093 | author name string | Steven Waggoner | |
| Kristine Zanotti | |||
| Analisa DiFeo | |||
| Kimberly Resnick | |||
| Sareena Singh | |||
| Anil Belur Nagaraj | |||
| Peronne Joseph | |||
| Raymond Redline | |||
| Amy Armstrong | |||
| Olga Kovalenko | |||
| P2860 | cites work | Niclosamide, an old antihelminthic agent, demonstrates antitumor activity by blocking multiple signaling pathways of cancer stem cells | Q27013612 |
| Cancer statistics, 2014 | Q27861018 | ||
| Lentivirus-delivered stable gene silencing by RNAi in primary cells | Q41996459 | ||
| Genetic and pharmacologic inhibition of β-catenin targets imatinib-resistant leukemia stem cells in CML. | Q42140104 | ||
| Integrating genomic, epigenomic, and transcriptomic features reveals modular signatures underlying poor prognosis in ovarian cancer. | Q44879961 | ||
| Cancer and stem cell biology: how tightly intertwined? | Q46026703 | ||
| Cancer stem cell definitions and terminology: the devil is in the details. | Q53140630 | ||
| Evolution of platinum resistance in high-grade serous ovarian cancer | Q58613175 | ||
| beta-catenin nuclear localization is associated with grade in ovarian serous carcinoma | Q73153525 | ||
| Lgr5 marks stem/progenitor cells in ovary and tubal epithelia | Q88222343 | ||
| Wnt signaling mediates regional specification in the vertebrate face | Q28588683 | ||
| WNT signalling pathways as therapeutic targets in cancer | Q29615666 | ||
| Loss of E-cadherin promotes metastasis via multiple downstream transcriptional pathways | Q29615855 | ||
| β-Catenin-regulated ALDH1A1 is a target in ovarian cancer spheroids | Q30370274 | ||
| Linking proteomic and transcriptional data through the interactome and epigenome reveals a map of oncogene-induced signaling | Q30588679 | ||
| A small molecule inhibitor of beta-catenin/CREB-binding protein transcription [corrected] | Q31106002 | ||
| Stem cell pathways contribute to clinical chemoresistance in ovarian cancer | Q34092005 | ||
| Ovarian surface epithelium at the junction area contains a cancer-prone stem cell niche | Q34331396 | ||
| Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer | Q34420393 | ||
| Ovarian cancer stem cell-like side populations are enriched following chemotherapy and overexpress EZH2. | Q34569371 | ||
| ALDH1-high ovarian cancer stem-like cells can be isolated from serous and clear cell adenocarcinoma cells, and ALDH1 high expression is associated with poor prognosis | Q34769665 | ||
| Ovarian cancer stem cells are enriched in side population and aldehyde dehydrogenase bright overlapping population | Q34962206 | ||
| Aldehyde dehydrogenase in combination with CD133 defines angiogenic ovarian cancer stem cells that portend poor patient survival | Q35022205 | ||
| Diverse mechanisms for activation of Wnt signalling in the ovarian tumour microenvironment | Q35098085 | ||
| Acquired cisplatin resistance in human ovarian cancer cells is associated with enhanced repair of cisplatin-DNA lesions and reduced drug accumulation | Q35818950 | ||
| Determining mammosphere-forming potential: application of the limiting dilution analysis | Q36192058 | ||
| Targeting Notch, a key pathway for ovarian cancer stem cells, sensitizes tumors to platinum therapy | Q36378255 | ||
| Wnt signaling in ovarian tumorigenesis | Q36953825 | ||
| Wnt/β-catenin Signaling in Normal and Cancer Stem Cells. | Q37132716 | ||
| WNT signalling in the immune system: WNT is spreading its wings | Q37212748 | ||
| microRNA-181a has a critical role in ovarian cancer progression through the regulation of the epithelial-mesenchymal transition. | Q37497239 | ||
| Genomic and transcriptomic plasticity in treatment-naive ovarian cancer | Q37550198 | ||
| Wnt/β-catenin pathway as a potential prognostic and predictive marker in patients with advanced ovarian cancer | Q37589190 | ||
| Targeting Wnt signaling: can we safely eradicate cancer stem cells? | Q37763415 | ||
| Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways | Q37820099 | ||
| Cancerous ovarian stem cells: obscure targets for therapy but relevant to chemoresistance. | Q38034167 | ||
| The role of aldehyde dehydrogenase (ALDH) in cancer drug resistance. | Q38110652 | ||
| Ovarian cancer stem cells: Molecular concepts and relevance as therapeutic targets | Q38118011 | ||
| The Wnt/β-catenin pathway in ovarian cancer: a review. | Q38152532 | ||
| Investigating molecular profiles of ovarian cancer: an update on cancer stem cells. | Q38203882 | ||
| Inhibition of Wnt/β-catenin pathway by niclosamide: a therapeutic target for ovarian cancer. | Q39003793 | ||
| ALDH1-bright epithelial ovarian cancer cells are associated with CD44 expression, drug resistance, and poor clinical outcome | Q39417011 | ||
| Cisplatin treatment of primary and metastatic epithelial ovarian carcinomas generates residual cells with mesenchymal stem cell-like profile. | Q39535066 | ||
| β-Catenin mediates the establishment and drug resistance of MLL leukemic stem cells | Q39620290 | ||
| The Origins and Implications of Intratumor Heterogeneity | Q40015673 | ||
| P433 | issue | 27 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | platinum | Q880 |
| ovarian cancer | Q172341 | ||
| P304 | page(s) | 23720-23734 | |
| P577 | publication date | 2015-06-29 | |
| P1433 | published in | Oncotarget | Q1573155 |
| P1476 | title | Critical role of Wnt/β-catenin signaling in driving epithelial ovarian cancer platinum resistance | |
| P478 | volume | 6 |
| Q39453727 | 'Lnc'-ing Wnt in female reproductive cancers: therapeutic potential of long non-coding RNAs in Wnt signalling. |
| Q90736000 | A Novel Role for the Tumor Suppressor Gene ITF2 in Tumorigenesis and Chemotherapy Response |
| Q60918023 | A miRNA-Mediated Approach to Dissect the Complexity of Tumor-Initiating Cell Function and Identify miRNA-Targeting Drugs |
| Q92767263 | AKIP1 promotes early recurrence of hepatocellular carcinoma through activating the Wnt/β-catenin/CBP signaling pathway |
| Q37520321 | Altered glutamine metabolism in platinum resistant ovarian cancer |
| Q92738227 | An 8‑gene signature predicts the prognosis of cervical cancer following radiotherapy |
| Q26744536 | Anti-Cancer Stem-like Cell Compounds in Clinical Development - An Overview and Critical Appraisal |
| Q91004442 | BRMS1L suppresses ovarian cancer metastasis via inhibition of the β-catenin-wnt pathway |
| Q41611914 | CD55 regulates self-renewal and cisplatin resistance in endometrioid tumors. |
| Q60125674 | CDMP1 overexpression mediates inflammatory cytokine‑induced apoptosis via inhibiting the Wnt/β‑Catenin pathway in rat dorsal root ganglia neurons |
| Q42378297 | Canonical and non-canonical WNT signaling in cancer stem cells and their niches: Cellular heterogeneity, omics reprogramming, targeted therapy and tumor plasticity (Review) |
| Q92263936 | Chemotherapy-Induced Distal Enhancers Drive Transcriptional Programs to Maintain the Chemoresistant State in Ovarian Cancer |
| Q37327524 | Cisplatin induces stemness in ovarian cancer |
| Q37595865 | Curcumin Inhibits Gastric Carcinoma Cell Growth and Induces Apoptosis by Suppressing the Wnt/β-Catenin Signaling Pathway. |
| Q38728565 | Developmental pathways associated with cancer metastasis: Notch, Wnt, and Hedgehog |
| Q47277352 | Dietary compound proanthocyanidins from Chinese bayberry (Myrica rubra Sieb. et Zucc.) leaves attenuate chemotherapy-resistant ovarian cancer stem cell traits via targeting the Wnt/β-catenin signaling pathway and inducing G1 cell cycle arrest |
| Q26752688 | Drug Delivery Using Nanoparticles for Cancer Stem-Like Cell Targeting |
| Q57296922 | Evaluating class III antiarrhythmic agents as novel MYC targeting drugs in ovarian cancer |
| Q83229853 | FAK activity sustains intrinsic and acquired ovarian cancer resistance to platinum chemotherapy |
| Q64064084 | Functional and transcriptomic characterization of carboplatin-resistant A2780 ovarian cancer cell line |
| Q37747417 | GOLPH3 induces epithelial-mesenchymal transition via Wnt/β-catenin signaling pathway in epithelial ovarian cancer |
| Q37520145 | Genetic variants of lncRNA HOTAIR and risk of epithelial ovarian cancer among Chinese women |
| Q58563343 | High expression of WNT7A predicts poor prognosis and promote tumor metastasis in pancreatic ductal adenocarcinoma |
| Q98777898 | Human-Derived Model Systems in Gynecological Cancer Research |
| Q38732555 | InFlo: a novel systems biology framework identifies cAMP-CREB1 axis as a key modulator of platinum resistance in ovarian cancer |
| Q47146356 | Increased PDGFR-beta and VEGFR-2 protein levels are associated with resistance to platinum-based chemotherapy and adverse outcome of ovarian cancer patients. |
| Q37286094 | KIAA0101, a target gene of miR-429, enhances migration and chemoresistance of epithelial ovarian cancer cells |
| Q49209136 | LGR5 and LGR6 in stem cell biology and ovarian cancer |
| Q48132307 | LncRNA PTCSC3/miR-574-5p Governs Cell Proliferation and Migration of Papillary Thyroid Carcinoma via Wnt/β-Catenin Signaling. |
| Q61448059 | LncRNA UCA1 promotes cell proliferation, invasion and migration of laryngeal squamous cell carcinoma cells by activating Wnt/β-catenin signaling pathway |
| Q41701933 | Metastasis-associated in colon cancer 1: A promising biomarker for the metastasis and prognosis of colorectal cancer |
| Q98658021 | MicroRNA-302 represses epithelial-mesenchymal transition and cisplatin resistance by regulating ATAD2 in ovarian carcinoma |
| Q52321991 | Mitotic Exit dysfunction through the deregulation of APC/C characterizes cisplatin resistant state in epithelial ovarian cancer. |
| Q37708047 | Molecular Classification of Lobular Carcinoma of the Breast |
| Q58790384 | Notch3-dependent β-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC |
| Q37233378 | Novel targeted therapies in adrenocortical carcinoma. |
| Q93007127 | Overcoming Resistance to Platinum-Based Drugs in Ovarian Cancer by Salinomycin and Its Derivatives-An In Vitro Study |
| Q38621094 | Pathways to Genome-targeted Therapies in Serous Ovarian Cancer |
| Q91826369 | Pharmacogenomic landscape of patient-derived tumor cells informs precision oncology therapy |
| Q64079995 | Programmed cell death ligand 1 (PD-L1) blockade attenuates metastatic colon cancer growth in cAMP-response element-binding protein (CREB)-binding protein (CBP)/β-catenin inhibitor-treated livers |
| Q51415152 | Rab14 is overexpressed in ovarian cancers and promotes ovarian cancer proliferation through Wnt pathway. |
| Q58734416 | Recurrent WNT pathway alterations are frequent in relapsed small cell lung cancer |
| Q58796642 | SLC6A1-miR133a-CDX2 loop regulates SK-OV-3 ovarian cancer cell proliferation, migration and invasion |
| Q41781737 | TLE4 regulation of wnt-mediated inflammation underlies its role as a tumor suppressor in myeloid leukemia |
| Q94553404 | Targeting Pyruvate Carboxylase by a Small Molecule Suppresses Breast Cancer Progression |
| Q64937696 | Targeting cancer stem cell signature gene SMOC-2 Overcomes chemoresistance and inhibits cell proliferation of endometrial carcinoma. |
| Q46021160 | Targeting the Wnt/beta-catenin pathway in cancer: Update on effectors and inhibitors. |
| Q28076473 | The Impact of Chemotherapy, Radiation and Epigenetic Modifiers in Cancer Cell Expression of Immune Inhibitory and Stimulatory Molecules and Anti-Tumor Efficacy |
| Q92714964 | The expressions of YAP1, β-catenin and survivin in colon cancer tissues and their clinical significance |
| Q37553760 | The iron chelator Dp44mT suppresses osteosarcoma's proliferation, invasion and migration: in vitro and in vivo |
| Q28069049 | The role of tumor microenvironment in therapeutic resistance |
| Q37500884 | Tobacco Mosaic Virus Delivery of Phenanthriplatin for Cancer therapy. |
| Q36067023 | Transmembrane protein 88 (TMEM88) promoter hypomethylation is associated with platinum resistance in ovarian cancer |
| Q48644072 | Using a novel computational drug-repositioning approach (DrugPredict) to rapidly identify potent drug candidates for cancer treatment |
| Q38429480 | Wnt/β-catenin signaling pathway inhibits the proliferation and apoptosis of U87 glioma cells via different mechanisms |
| Q91910450 | Wnt/β-catenin signalling in ovarian cancer: Insights into its hyperactivation and function in tumorigenesis |
| Q37427658 | Wnt5a Increases Properties of Lung Cancer Stem Cells and Resistance to Cisplatin through Activation of Wnt5a/PKC Signaling Pathway. |
| Q36782334 | miR-30a inhibits endothelin A receptor and chemoresistance in ovarian carcinoma |
| Q64062024 | miR-340-FHL2 axis inhibits cell growth and metastasis in ovarian cancer |
| Q64251972 | miR-590-3p Targets Cyclin G2 and FOXO3 to Promote Ovarian Cancer Cell Proliferation, Invasion, and Spheroid Formation |
| Q50560992 | β-catenin downregulates Dicer to promote ovarian cancer metastasis. |
Search more.